One vaccine may provide broad protection against many respiratory infections and allergens

Stanford Medicine researchers and their colleagues invented a new vaccine that protects mice from respiratory viruses, bacteria and allergens — the closest yet to a universal vaccine.

La grotte

How to avoid catching flu, COVID-19 and other respiratory illnesses this winter  – UK Health Security Agency

As we brace ourselves for chillier days and look forward to more indoor gatherings and seasonal social events with friends and family, now is the ideal time to remind ourselves of guidance on vaccination, isolation, good respiratory etiquette, mask wearing,

RSV gây nhiễm trùng hô hấp dưới, đe dọa sức khỏe trẻ nhũ nhi và người cao tuổi

Hội nghị do Hội Hô hấp Việt Nam và Pfizer Việt Nam tổ chức quy tụ hàng trăm cán bộ y tế bàn giải pháp phòng ngừa RSV bảo vệ trẻ nhũ nhi và người cao tuổi.

The Role Of Vitamin D Supplementation In The Prevention Of Acute Respiratory Infections: A Double-Blind Randomized Controlled Trial

<p><strong>Background: </strong>Acute respiratory infections (ARIs) remain among the most common causes of morbidity and mortality worldwide, particularly in children, the elderly, and immunocompromised individuals. Emerging evidence suggests that vitamin D, …</p>

OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial

The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.

Multiorgan sequelae following non-COVID-19 respiratory infections: a review - Infection

Background While numerous studies have documented severe and long-term health impacts of COVID-19 infections on various organs, the prolonged multisystemic implications of other acute respiratory infections (ARIs) are poorly understood. This review therefore analyzed currently available studies about these sequelae of ARIs excluding COVID-19. Main body Multiple pathogens causing ARIs are associated with significant long-lasting impairments across various organ systems. Cardiovascular events occur in 10–35% of patients following ARIs, with an elevated risk persisting for 10 years. The stroke incidence ratio increases significantly after ARIs up to 12.3. Pulmonary sequelae are common, including abnormal lung function in 54%, parenchymal opacification in 51%, lung fibrosis in 33–62%, asthma in 30%, and bronchiectasis in 24% of patients. The risk of developing dementia is increased 2.2-fold. Posttraumatic stress disorder, depression, anxiety, and chronic fatigue occur in 15–43%, 15–36%, 14–62%, and 27–75% of patients, respectively. 28-day mortality from CAP with (versus no) additional cardiovascular event is increased to 36% (versus 10%). Long-term mortality from CAP (versus no CAP) remains elevated for years post-infection, with a 1-year, 5-year, and 7-year mortality rate of 17% (versus 4%), 43% (versus 19%), and 53% (versus 24%), respectively. Patients´ quality of life is significantly reduced, with 17% receiving invalidity pensions and 22% retiring within 4 years of severe ARIs. Conclusion Non-COVID-19 ARIs are associated with clinically relevant, frequent, and long-term sequelae involving multiple organ systems. Further prospective studies are needed.